| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MSJ.21302 |
| P698 | PubMed publication ID | 22499489 |
| P2093 | author name string | Thomas D Schiano | |
| Kieron B L Lim | |||
| P2860 | cites work | Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols | Q27477631 |
| Predictive Factors Associated with the Reversibility of Post-transplantation Diabetes Mellitus Following Liver Transplantation | Q27489042 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Chronic renal failure after transplantation of a nonrenal organ | Q28204928 | ||
| The quality of health care delivered to adults in the United States | Q29616225 | ||
| Viral infections in immunocompromised patients: what's new with respiratory viruses? | Q30309653 | ||
| Improvement in survival associated with adult-to-adult living donor liver transplantation | Q30430728 | ||
| Posttransplantation diabetes: a systematic review of the literature | Q30821989 | ||
| Vaccination, screening for malignancy, and health maintenance of the liver transplant recipient | Q32015828 | ||
| A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts | Q32048820 | ||
| Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience | Q33263334 | ||
| New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies | Q33407635 | ||
| De novo malignancies following liver transplantation: a case-control study with long-term follow-up | Q33730925 | ||
| Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study | Q33937741 | ||
| Defining patient risks from expanded preventive therapies | Q33945562 | ||
| MELD and PELD: application of survival models to liver allocation | Q33953612 | ||
| Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin | Q46162126 | ||
| De novo nonalcoholic fatty liver disease after liver transplantation | Q46201190 | ||
| Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies | Q46203119 | ||
| Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. | Q46220650 | ||
| Erectile dysfunction in liver transplant patients. | Q46317689 | ||
| Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial | Q46364237 | ||
| Weight gain and obesity after liver transplantation | Q46386635 | ||
| Renal histopathological lesions after orthotopic liver transplantation (OLT). | Q46427156 | ||
| Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. | Q46453052 | ||
| Mechanisms of hypertension after liver transplantation | Q46453786 | ||
| Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation | Q46580991 | ||
| Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study | Q46611597 | ||
| Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation | Q46654068 | ||
| New-onset diabetes after liver transplantation | Q46719525 | ||
| Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients | Q46954385 | ||
| Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial | Q46954457 | ||
| Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study | Q46962146 | ||
| Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation | Q47960515 | ||
| Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. | Q50723989 | ||
| Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). | Q50878999 | ||
| Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. | Q51131902 | ||
| Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. | Q51466759 | ||
| Diabetes mellitus after kidney transplantation: a French multicentre observational study. | Q51474073 | ||
| Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. | Q51482450 | ||
| Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors. | Q51737005 | ||
| Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. | Q51755737 | ||
| Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. | Q51771916 | ||
| Chronic kidney disease post-liver transplantation. | Q51802543 | ||
| Sexual functioning in patients with end-stage liver disease before and after transplantation. | Q53004755 | ||
| Hepatorenal syndrome | Q56683659 | ||
| Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation | Q57168211 | ||
| Effects of Smoking on Survival for Patients with End-Stage Liver Disease | Q57653130 | ||
| Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report | Q58283831 | ||
| Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy | Q58284183 | ||
| Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review | Q37770120 | ||
| Posttransplant lymphoproliferative disease following liver transplantation | Q37862042 | ||
| Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales | Q38471669 | ||
| Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey. | Q38943572 | ||
| Long-term management after liver transplantation: primary care physician versus hepatologist | Q39943054 | ||
| Bone disease in cholestatic liver disease | Q40560142 | ||
| Influenza virus infection in adult solid organ transplant recipients | Q40579386 | ||
| Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant | Q40873409 | ||
| Hyperlipidemia in solid organ transplantation. | Q41353423 | ||
| The impact of obesity on surgical outcomes: a review | Q41665784 | ||
| Surgical implications of obesity | Q41724113 | ||
| Nonmelanoma skin cancer after liver transplantation. Study of risk factors. | Q42483204 | ||
| Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation | Q42521196 | ||
| High rate of unemployment after liver transplantation: analysis of the United Network for Organ Sharing database | Q42612789 | ||
| Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database | Q42656443 | ||
| Obesity increases mortality in liver transplantation--the Danish experience | Q42670504 | ||
| Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation | Q42675292 | ||
| Hypomagnesemia and the risk of new-onset diabetes after liver transplantation | Q42843887 | ||
| 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus | Q43031760 | ||
| Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. | Q43032825 | ||
| Depressive symptoms predict long-term mortality after liver transplantation. | Q43037636 | ||
| Insulin resistance, hepatitis C, and liver transplantation | Q43047351 | ||
| Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". | Q43205304 | ||
| Obesity, hyperlipidemia, and metabolic syndrome | Q43251981 | ||
| Outcomes after liver transplantation: chronic kidney disease | Q43252005 | ||
| Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study | Q43283437 | ||
| Impact of renal failure on liver transplantation survival | Q43411131 | ||
| Re-weighting the model for end-stage liver disease score components | Q43508410 | ||
| In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosis | Q43611611 | ||
| De novo tumors after liver transplantation: a single-institution experience | Q43620047 | ||
| Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial | Q43701061 | ||
| Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality | Q43752482 | ||
| End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment | Q43843805 | ||
| Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States | Q43851672 | ||
| Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. | Q43963125 | ||
| Post-liver transplantation diabetes mellitus: an association with hepatitis C. | Q43966879 | ||
| Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy | Q44013375 | ||
| Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. | Q44036839 | ||
| Chronic renal dysfunction late after liver transplantation | Q44165114 | ||
| Inhibition of intestinal cholesterol absorption by ezetimibe in humans | Q44172138 | ||
| Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding | Q44491104 | ||
| The effects of hyperlipidaemia on graft and patient outcome in renal transplantation | Q44491679 | ||
| Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality | Q44577644 | ||
| Chronic kidney disease following liver transplantation: a South Australian experience | Q44587764 | ||
| Sexual health after orthotopic liver transplantation | Q44629752 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients | Q44713794 | ||
| Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients | Q44741576 | ||
| The impact of liver transplantation on endocrine status in men. | Q44746617 | ||
| Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations | Q44755723 | ||
| New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. | Q44789148 | ||
| Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research | Q44789163 | ||
| De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? | Q44800851 | ||
| Metabolic syndrome after liver transplantation: prevalence and predictive factors | Q45153146 | ||
| Acute renal failure after cadaveric related liver transplantation | Q45160781 | ||
| Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis | Q45196853 | ||
| Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus | Q45403442 | ||
| Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation | Q45665322 | ||
| Menstrual function in female liver transplant recipients of reproductive age. | Q45958475 | ||
| Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. | Q45962265 | ||
| Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. | Q45964495 | ||
| Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. | Q46033909 | ||
| Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels | Q46045876 | ||
| Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. | Q46045883 | ||
| Epstein-Barr virus infection | Q34004958 | ||
| Posttransplantation hypertension related to calcineurin inhibitors | Q34026776 | ||
| Influenza infection in patients before and after liver transplantation | Q34026783 | ||
| Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview | Q34043993 | ||
| Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival | Q34046222 | ||
| Hepatic osteodystrophy. | Q34109988 | ||
| Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years | Q34287276 | ||
| Kidney transplantation under FK 506 | Q34302082 | ||
| Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity | Q34426367 | ||
| Hypertension and renal dysfunction in long-term liver transplant recipients | Q34426372 | ||
| Rapamycin: an anti-cancer immunosuppressant? | Q34436339 | ||
| Drug-related hepatotoxicity | Q34495071 | ||
| Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. | Q34510743 | ||
| Managing dyslipidemia in the high-risk patient | Q34568566 | ||
| Identification of patients best suited for combined liver-kidney transplantation: part II. | Q34575149 | ||
| Immunisations in solid-organ transplant recipients | Q34579905 | ||
| Cardiovascular morbidity and mortality after orthotopic liver transplantation | Q34581979 | ||
| The liver and lovastatin | Q34683472 | ||
| The burden of chronic kidney disease in long-term liver transplant recipients. | Q34790359 | ||
| Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management | Q34861980 | ||
| Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre | Q34959580 | ||
| Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance | Q34993507 | ||
| Infections in liver transplant recipients. | Q34993661 | ||
| Severe vitamin D deficiency among heart and liver transplant recipients | Q35091888 | ||
| New onset diabetes after transplantation (NODAT): an overview | Q35092351 | ||
| New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. | Q35140602 | ||
| AGA technical review on osteoporosis in hepatic disorders. | Q35209520 | ||
| The impact of the model for end-stage liver disease on recipient selection for adult living liver donation | Q35551271 | ||
| New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis | Q35691924 | ||
| New-onset diabetes after transplantation. | Q35749469 | ||
| Prevention of infection in adult travelers after solid organ transplantation | Q36001738 | ||
| Gonadal dysfunction in systemic diseases | Q36092338 | ||
| Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients | Q36111146 | ||
| Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions | Q36116459 | ||
| Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation | Q36155827 | ||
| Survival after liver transplantation in the United Kingdom and Ireland compared with the United States | Q36172774 | ||
| Incidence and risk factors for cancer after liver transplantation. | Q36175674 | ||
| Kidney dysfunction in the recipients of liver transplants | Q36291834 | ||
| Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? | Q36317848 | ||
| Nonalcoholic fatty liver disease and liver transplantation. | Q36429189 | ||
| Liver disease and osteoporosis. | Q36506087 | ||
| Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients | Q36519141 | ||
| Post-transplant de novo malignancies in renal transplant recipients: the past and present | Q36530274 | ||
| Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. | Q36547798 | ||
| Statins and solid organ transplantation. | Q36683681 | ||
| Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. | Q36696738 | ||
| Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence | Q36936421 | ||
| Bone disorders in chronic liver disease | Q36948504 | ||
| Chronic kidney disease after nonrenal solid-organ transplantation | Q37015132 | ||
| Update on immunizations in solid organ transplant recipients: what clinicians need to know | Q37037796 | ||
| Infection in solid-organ transplant recipients | Q37038203 | ||
| Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients | Q37064456 | ||
| Quality of life after liver transplantation. A systematic review | Q37086433 | ||
| Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation | Q37092562 | ||
| Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues | Q37149717 | ||
| Transplant-associated hyperglycemia | Q37218096 | ||
| Pregnancy after transplantation | Q37240691 | ||
| Pregnancy after solid organ transplantation | Q37283100 | ||
| The role of mTOR inhibitors in the management of posttransplant malignancy | Q37373320 | ||
| Liver transplantation: the current situation | Q37398943 | ||
| Long-term probability of and mortality from de novo malignancy after liver transplantation | Q37463619 | ||
| Effect of bisphosphonates on bone mineral density in liver transplant patients: a meta-analysis and systematic review of randomized controlled trials | Q37605901 | ||
| Posttransplant metabolic syndrome: an epidemic waiting to happen | Q37638639 | ||
| Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up | Q37680624 | ||
| Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. | Q37737366 | ||
| Metabolic syndrome and liver transplantation: a review and guide to management | Q37745416 | ||
| Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? | Q37750452 | ||
| Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management | Q37760607 | ||
| P433 | issue | 2 | |
| P921 | main subject | liver transplantation | Q1368191 |
| P304 | page(s) | 169-189 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Mount Sinai Journal of Medicine | Q6923672 |
| P1476 | title | Long-term outcome after liver transplantation. | |
| P478 | volume | 79 |
| Q38862725 | Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients |
| Q42480438 | Immune monitoring of immunosuppression withdrawal of liver transplant recipients |
| Q51194001 | Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. |
| Q38503362 | Outcomes of pregnancy following liver transplantation: The King's College Hospital experience |
| Q92762566 | Sinusoidal and pericellular fibrosis in adult post-transplant liver biopsies: association with hepatic stellate cell activation and patient outcome |
| Q39968125 | Study of the Role of Transforming Growth Factor β-1 in Organ Damage Protection in Porcine Model of Brain Death |
| Q48400097 | The effect of self-efficacy, depression and symptom distress on employment status and leisure activities of liver transplant recipients. |
| Q42440224 | Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance |
Search more.